| SciPort RLP

2014 - 2018

Energy metabolism in ovarian cancer

Dr. Marco Johannes,
PD Dr. Stefan,
Univ.-Prof. Dr. Wolfgang,
Univ.-Prof. Dr. Marcus,
Univ.-Prof. Dr. Annette

2014 - 2016

Role of p53, XIAP and Survivin in the resistence of tumor cells against alkylating anticancer drugs

PD Dr. Maja

2014 - 2019

Clinical phase III trial to compare Treosulfan-based conditioning therapy with Busulfan-based reduced-intensity conditioning (RIC) prior to allogeneic haematopoietic stem cell transplantation in patients with AML or MDS considered ineligible to standard conditioning regimens (#542)

Dr. Eva Maria

2014 - 2016

COMBO DTS.de Register

Univ.-Prof. Dr. Tommaso

2014 - 2017

A Randomized, Open-label, Phase 3 Study of Carfilzomib, Melphalan, and Prednisone versus Bortezomib, Melphalan, and Prednisone in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma (#516)

PD Dr. Markus

2014 - 2017

Forschungszentrum Immunologie (FZI), Asthma Core Facility CF1

PD Dr. M

2014 - 2016

Direct Flow Discover Register

Univ.-Prof. Dr. Ulrich

2014 - 2019

Pomalidomid/Dexamethason und remissionsabhängig Cyclophosphamid bei Myelom-Rezidiv (#550)

PD Dr. Markus

2014 - 2017

Forschungszentrum Immunologie (FZI), Core Facility Massenspektrometrie CF7

Dr. Stefan

2014 - 2021

A randomized, double-blind, placebo-controlled phase 3 study of the Bruton’s Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in combination with either Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in subjects with previously treated indolent Non-Hodgkin Lymphoma (iNHL) (#551)

Univ.-Prof. Dr. Georg

FB 04 - Universitätsmedizin

Johannes Gutenberg-Universität Mainz

Starten Sie Ihre Suche...

FB 04 - Universitätsmedizin

Johannes Gutenberg-Universität Mainz